The NASDAQ Biotech Stock to Watch in 2022

Positive Phase 1 Data Has Just Been Released as This Emerging Company Aims to Succeed in the Massive TNF Blocker Market that Has Made Humira Nearly $20B!   Teamed with industry leaders in science, this emerging biotech company is targeting age related diseases as well as auto-immune, chronic pain, and anxiety and sleep disorders. The company has partnered with academic founders and key opinion leaders to identify synthetic therapeutics, including the very first drug the company is aware of that is being designed to significantly delay aging!   The company recently released Phase 1 clinical trial data that demonstrates their drug had a reduction of tumor necrosis factor-alpha (TNF-α) in the blood of healthy HUMAN subjects. In other words. Phase-1 dose-ranging study results meet primary endpoints, and the drug demonstrates statistically significant efficacy in reducing TNF-α in the blood! Why is this so significant? TNF-α are the molecules that are the root cause of aging! According to the company, there are NO FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be $600 billion by 2025.   See how this company's drug platforms are seeking to become best-in-class treatments for some of the most notorious diseases and disorders!

This email was sent to edwardlorilla1986.paxforex@blogger.com by editor@marketmovingtrends.com MarketMovingTrends, 45 South Park Place, #203, Morristown, NJ 07960 United States   Unsubscribe | Report Spam